Global health security is a growing field that continues to evolve. The COVID-19 pandemic has especially emphasised the greatest needs and opportunities for progress in low- and middle-income countries, where systems are not yet in place to address emerging infectious disease threats, as well as in high-income countries, which also present large systems-related gaps. Developing public health systems is, therefore, very important. Dr Leonard Peruski (Centers for Disease Control and Prevention, US) talked to us about the laboratory response to COVID-19, how it has evolved and what important lessons were learned from the pandemic.
Evolution of the Laboratory Response to COVID-19 and Priorities for the Future’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- How has the laboratory response to COVID-19 evolved over the course of the pandemic? (00:38)
- What have been the most important lessons learned? (03:52)
Disclosures: Leonard Peruski has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]